Join AABB® and Be The Match BioTherapies® in San Antonio this fall for an interactive workshop and collaborative learning opportunity that will unpack real-world scenarios highlighting the challenges of implementing cellular therapies across various settings and business models.

The workshop will explore the perspectives of hospitals, blood centers and small startup companies with both centralized and decentralized manufacturing models. Join us for an afternoon of collaborative learning and deep discussion with world-renowned faculty.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 12:00 pm–1:00 pm | **Opening Session: Manufacturing Challenges in Implementing Cellular Therapy Services**  
This fireside chat will address the challenges and hurdles inherent to working in the cell and gene therapy industry. Participants will discuss successes, setbacks, and lessons learned as a result of sustained industry experience.  
**Moderators:**  
Magali Fontaine, MD, PhD  
Professor, Department of Pathology and Medicine  
University of Maryland School of Medicine  
Chair, Workshop Planning Committee  
Amy Hines, RN, BSN  
Director, Collection Experience  
National Marrow Donor Program®/Be The Match®  
**Panelists:**  
Joseph McGuirk, DO  
Professor, Hematology-Oncology  
Division Director, Hematologic Malignancies and Cellular Therapeutics  
Medical Director, Blood and Marrow Transplant  
The University of Kansas Medical Center  
Robert Tressler, PhD, MS  
Vice President, Laboratories  
San Diego Blood Bank  
John McMannis, PhD  
Executive Vice President, Manufacturing  
Mesoblast, Inc. |
| 1:00 pm–2:00 pm | **Lunch**                                                              |
| 2:00 pm–2:45 pm | **Plenary Session: Inroads to Response and Resistance in CAR-T Cell Therapy**  
**Moderator:**  
Mark Flower  
Senior Director, Sales and New Business Development  
Be The Match BioTherapies® |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Moderator</th>
<th>Speakers</th>
</tr>
</thead>
</table>
| 2:45 pm – 3:15 pm | **Mechanisms of Tumor Escape from CAR-T Cell Therapy: Challenges and Solutions**                                                             | Mark Flower                                                              | Mohamad Hamieh, PhD  
Research Associate  
Dr. Michel Sadelain Lab Center for Cell Engineering, Memorial Sloan Kettering Cancer Center |
| 3:15 pm – 3:45 pm | **The Therapeutic Use of Extracellular Vesicles by MSC: Improving Right Ventricular Function and Pulmonary Fibrosis With MSC Derived Exosomes** |                                                                                  | Luis A Ortiz, MD  
Professor, Department of Environmental and Occupational Medicine  
Graduate School of Public Health and Professor, Department of Medicine  
University of Pittsburgh |
| 3:45 pm – 4:00 pm | **Break**                                                                                                                                     |                                                                          |                                                                                                   |
| 4:00 pm – 5:30 pm | **Breakout Sessions**                                                                                                                          |                                                                          |                                                                                                   |
|              | **Breakout Session A: New Cells on the Block**                                                                                              |                                                                          |                                                                                                   |
|              | This deep-dive session will highlight the latest scientific advancements in cellular-derived therapeutics, including exosomes, microparticles and emerging devices for delivery. |                                                                          |                                                                                                   |
|              | **Moderator:**  
**Magali Fontaine, MD, PhD**  
Professor, Department of Pathology and Medicine  
University of Maryland School of Medicine |                                                                          |                                                                                                   |
|              | **Speakers:**                                                                                                                                |                                                                          |                                                                                                   |
Patrick Hanley, PhD  
*Director, Cellular Therapy Laboratory*  
Children's National Medical Center  
*Assistant Professor, Pediatrics*  
George Washington University

Presentation: Optimizing the Manufacture of MSCs and T cells for Phase 1 Clinical Trials

Aisha Khan, PhDc, MSc, MBA  
*Executive Director, Laboratory Operations*  
Miller School of Medicine, The University of Miami

Presentation: Pre-Clinical and Clinical Cell Manufacturing

Andrew Rhim, MD  
*Assistant Professor*  
MD Anderson Cancer Center, The University of Texas

Presentation: The Role of Blood Banks in Personalized Cancer Care

**Breakout Session B: Ground-level Synergies for Novel Cell Therapies**  
This session will cover current strategies for donor selection, consent, and characterization as well as the latest advancements in the processing of source material for autologous and allogenic cell therapies.

**Moderator:**  
Christie Malone, MT (ASCP) SBB  
*Corporate Account Executive*  
GenCure Biomanufacturing

**Panelists:**  
John Armitage, MD  
*Chief Executive Officer and President*  
Oklahoma Blood Institute

Olive Sturtevant, MT(ASCP)SBB, CQA  
*Administrative Director*  
Connell & O'Reilly Families Cell Manipulation Core Facility, Dana Farber Cancer Institute

Timothy Sheehy  
*Director, Quality and Regulatory Affairs*  
Versiti Blood Center
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:30 pm</td>
<td><strong>Program Adjourns</strong></td>
</tr>
<tr>
<td>6:00 pm</td>
<td><strong>Cellular Therapies Network Reception</strong></td>
</tr>
</tbody>
</table>